Patents by Inventor John David Fraser

John David Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SSL7 MUTANTS AND USES THEREFOR
    Publication number: 20110027907
    Abstract: The invention relates to SSL7 mutants which have no, or at least reduced, ability to bind to IgA. The mutants have significant application in the purification or isolation of C5 from samples and in the identification or detection, including quantitation, of C5 in samples. Use of the mutants has the benefit of minimising or preventing simultaneous isolation and/or detection of IgA in a sample, simplifying and improving methods relying on wild type SSL7.
    Type: Application
    Filed: October 18, 2007
    Publication date: February 3, 2011
    Applicant: Auckland Uniservice Limited
    Inventors: John David Fraser, Bruce David Wines
  • SET1 proteins and uses thereof
    Patent number: 7838244
    Abstract: The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedure, for identification and/or isolation of IgA and the scrum complement factor C5.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: November 23, 2010
    Assignee: Auckland Uniservices Limited
    Inventors: John David Fraser, Ries Langley
  • Set1 proteins and uses thereof
    Publication number: 20090215195
    Abstract: The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedure, for identification and/or isolation of IgA and the scrum complement factor C5.
    Type: Application
    Filed: December 7, 2004
    Publication date: August 27, 2009
    Inventors: John David Fraser, Ries Langley
  • Immunomodulatory constructs and their uses
    Patent number: 7547769
    Abstract: The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: June 16, 2009
    Assignee: Auckland Uniservices Limited
    Inventor: John David Fraser
  • Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
    Patent number: 7491402
    Abstract: The invention provides superantigens SMEZ-2, SPE-G, SPE-H and SPE-J, as well as polynucleotides which encode them. Such superantigens have, inter alia, diagnostic and therapeutic application.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: February 17, 2009
    Assignee: Auckland Uniservices Limited
    Inventors: John David Fraser, Thomas Proft
  • Immunomodulatory constructs and their uses
    Publication number: 20030124142
    Abstract: An immunomodulator which includes an antigen-presenting-cell (APC) targeting molecule coupled to an immunomodulatory antigen, wherein the APC-targeting molecule mimics a superantigen but does not include a fully functional T-cell receptor binding site. Also disclosed are a method of therapeutic or prophylactic treatment of a disorder, including administrating to a subject in need thereof a pharmaceutical composition or a vaccine containing the immunomodulator; use of the immunomodulator for the preparation of a medicament for the therapeutic or prophylactic treatment of a disorder; and a method of preparing the immunomodulator.
    Type: Application
    Filed: December 4, 2001
    Publication date: July 3, 2003
    Inventors: John David Fraser, Melissa Joy Nicholson